Read up on base editing

Beam Therapeutics: Editing genomes, one letter at a time

FierceBiotech -

Drugs based on gene editing are still in the earliest stages of development, but that’s not stopping new players looking at refining and improving the technology. Beam Therapeutics—co-founded by a trio of top-flight CRISPR researchers—is focusing on a technique known as base editing that ups the ante on CRISPR’s precision by making it possible to find, remove and replace a single nucleotide base, or “letter,” without affecting those surrounding it.

View the news article online here.